DGAP-Adhoc: Shareholder B. Braun Melsungen AG demands convocation of extraordinary general share-holders' meeting in connection with takeover offer of Asklepios
DGAP-Ad-hoc: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): AGM/EGM/Offer
Shareholder B. Braun Melsungen AG demands convocation of extraordinary general share-holders' meeting in connection with takeover offer of Asklepios
18-Apr-2020 / 00:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Shareholder B. Braun Melsungen AG demands convocation of extraordinary general shareholders' meeting in connection with takeover offer of Asklepios
The Company today received a demand by the shareholder B. Braun Melsungen AG pursuant to Section 16 para. 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz - "WpÜG") and Section 122 para. 1 of the German Stock Corporation Act (Aktiengesetz - AktG) regarding the convocation of an extraordinary general shareholders' meeting in connection with the public takeover offer of Asklepios Kliniken GmbH & Co. KGaA ("Asklepios").
According to the convocation demand, the extraordinary general shareholders' meeting shall deal with the following agenda items:
- Discussion and eventually resolution on the takeover offer by Asklepios,
- Resolution on a change of the majority requirements for resolutions of the general shareholders' meeting pursuant to Section 17 no. 3 of the articles of association (increase to a majority of 75% of the votes cast or the registered share capital present, respectively),
- Dismissal of the Supervisory Board members Eugen Münch, Wolfgang Mündel, Prof. Dr. Gerhard Ehninger, Jan Hacker, Christine Reißner and Dr. Brigitte Mohn,
- Election of new Supervisory Board members of the shareholder side, and
- Resolution on the payment of an advance payment (Abschlag) of EUR 133,876,940.00 on the expected, fully distributable balance sheet profit, i.e. EUR 2.00 per RHÖN share.
The Management Board will carefully examine the request of B. Braun to convene an extraordinary general shareholders' meeting and take any legally required measures. In the event that an extraordinary general shareholders' meeting is convened pursuant to Section 16 para. 3 WpÜG in accordance with the request of Asklepios, the acceptance period for the takeover offer would be extended to ten weeks from the publication of the offer document (without prejudice to statutory provisions on a further extension).
18-Apr-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
RHÖN-KLINIKUM Aktiengesellschaft |
|
Salzburger Leite 1 |
|
97616 Bad Neustadt a.d.Saale |
|
Germany |
Phone: |
+49 (0)9771 - 65-0 |
Fax: |
+49 (0)9771 - 97 467 |
E-mail: |
[email protected] |
Internet: |
www.rhoen-klinikum-ag.com |
ISIN: |
DE0007042301 |
WKN: |
704230 |
Indices: |
SDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: |
1024569 |
|
End of Announcement |
DGAP News Service |
1024569 18-Apr-2020 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
1.211,08 |
1.232,91 |
1.303,90 |
1.360,16 |
1.402,01 |
1.446,09 |
1.463,98 |
EBITDA1,2 |
97,82 |
125,54 |
125,33 |
80,23 |
101,16 |
105,65 |
105,88 |
EBITDA-Marge3 |
8,08 |
10,18 |
9,61 |
5,90 |
7,22 |
7,31 |
|
EBIT1,4 |
38,70 |
64,94 |
56,80 |
10,60 |
30,52 |
36,11 |
40,40 |
EBIT-Marge5 |
3,20 |
5,27 |
4,36 |
0,78 |
2,18 |
2,50 |
2,76 |
Jahresüberschuss1 |
36,74 |
51,19 |
44,48 |
2,46 |
30,23 |
26,94 |
40,17 |
Netto-Marge6 |
3,03 |
4,15 |
3,41 |
0,18 |
2,16 |
1,86 |
2,74 |
Cashflow1,7 |
80,30 |
49,50 |
47,30 |
113,30 |
97,50 |
41,30 |
109,00 |
Ergebnis je Aktie8 |
0,53 |
0,73 |
0,65 |
0,02 |
0,42 |
0,38 |
0,58 |
Dividende8 |
0,22 |
0,29 |
0,00 |
0,00 |
0,00 |
0,15 |
0,35 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: KPMG
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Rhön-Klinikum |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
704230 |
13,200 |
Halten |
883,90 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
22,00 |
28,57 |
0,78 |
22,56 |
KBV |
KCV |
KUV |
EV/EBITDA |
0,71 |
8,11 |
0,60 |
7,76 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,15 |
0,00 |
0,00 |
05.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
08.05.2024 |
08.08.2024 |
07.11.2024 |
28.03.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
18,35% |
17,51% |
32,00% |
-0,75% |
|
|